DSKYF Quote, Financials, Valuation and Earnings

PeptiDream has a net margin of 12.77% compared to Daiichi Sankyo's net margin of -24.41%. Daiichi Sankyo's return on equity of 17.67% beat PeptiDream's return on equity of 34.1%.

Daiichi Sankyo has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Daiichi Sankyo has higher upside potential than PeptiDream, analysts believe Daiichi Sankyo is more attractive than PeptiDream.

Daiichi Sankyo has a beta of 0.494, which suggesting that the stock is 50.557% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.542, suggesting its less volatile than the S&P 500 by 45.756%.

Daiichi Sankyo has a quarterly dividend of $0.20 per share corresponding to a yield of 1.73%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daiichi Sankyo pays 38.65% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend. Daiichi Sankyo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Daiichi Sankyo quarterly revenues are $3.2B, which are larger than PeptiDream quarterly revenues of $27.8M. Daiichi Sankyo's net income of $406M is higher than PeptiDream's net income of -$6.8M. Notably, Daiichi Sankyo's price-to-earnings ratio is 22.69x while PeptiDream's PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daiichi Sankyo is 3.56x versus 5.17x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma has a net margin of 12.77% compared to Daiichi Sankyo's net margin of -11.44%. Daiichi Sankyo's return on equity of 17.67% beat Nxera Pharma's return on equity of -8.65%.

Daiichi Sankyo has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Daiichi Sankyo has higher upside potential than Nxera Pharma, analysts believe Daiichi Sankyo is more attractive than Nxera Pharma.

Daiichi Sankyo has a beta of 0.494, which suggesting that the stock is 50.557% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.360, suggesting its less volatile than the S&P 500 by 64.028%.

Daiichi Sankyo has a quarterly dividend of $0.20 per share corresponding to a yield of 1.73%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daiichi Sankyo pays 38.65% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend. Daiichi Sankyo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Daiichi Sankyo quarterly revenues are $3.2B, which are larger than Nxera Pharma quarterly revenues of $43.6M. Daiichi Sankyo's net income of $406M is higher than Nxera Pharma's net income of -$5M. Notably, Daiichi Sankyo's price-to-earnings ratio is 22.69x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daiichi Sankyo is 3.56x versus 3.51x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical has a net margin of 12.77% compared to Daiichi Sankyo's net margin of -9.79%. Daiichi Sankyo's return on equity of 17.67% beat Takeda Pharmaceutical's return on equity of 1.49%.

Daiichi Sankyo has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $17.15 which suggests that it could grow by 12.32%. Given that Takeda Pharmaceutical has higher upside potential than Daiichi Sankyo, analysts believe Takeda Pharmaceutical is more attractive than Daiichi Sankyo.

Daiichi Sankyo has a beta of 0.494, which suggesting that the stock is 50.557% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.227, suggesting its less volatile than the S&P 500 by 77.347%.

Daiichi Sankyo has a quarterly dividend of $0.20 per share corresponding to a yield of 1.73%. Takeda Pharmaceutical offers a yield of 4.02% to investors and pays a quarterly dividend of $0.33 per share. Daiichi Sankyo pays 38.65% of its earnings as a dividend. Takeda Pharmaceutical pays out 280.28% of its earnings as a dividend. Daiichi Sankyo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical's is not.

Daiichi Sankyo quarterly revenues are $3.2B, which are smaller than Takeda Pharmaceutical quarterly revenues of $6.9B. Daiichi Sankyo's net income of $406M is higher than Takeda Pharmaceutical's net income of -$676.5M. Notably, Daiichi Sankyo's price-to-earnings ratio is 22.69x while Takeda Pharmaceutical's PE ratio is 70.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daiichi Sankyo is 3.56x versus 1.65x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.